| Předmět: |
|
| Zdroj: |
Clinical Oncology Week; 2/6/2024, p1075-1075, 1p |
| Abstrakt: |
A recent study conducted by the National Cancer Institute (NCI) in Ukraine explored the potential of combining liposomal doxorubicin (LDOX) with inductive moderate hyperthermia (IMH) for the treatment of osteosarcoma (OS). The researchers found that the combination treatment resulted in a significant decrease in cell viability compared to no treatment. Additionally, IMH enhanced the delivery of LDOX and its antitumor effect by promoting the production of reactive oxygen species (ROS) at temperatures below 42 °C. These findings suggest that further research should be conducted to explore the potential translation of these results into in vivo studies. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
